Commercial Aquaculture Vaccine Market
Commercial Aquaculture Vaccine Market Study by Inactivated, Attenuated, Subunit, and DNA for Fish Farming Companies, Fish Veterinary Clinics, and Aquatic Research Institutes from 2024 to 2034
Analysis of Commercial Aquaculture Vaccine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
- FACT9577MR
- 09 Jan 2024
- Healthcare
- 170 Pages
- 30 Tables
- 127 Figures
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Market Background
- 5. Market Context
- 6. Global Market - Pricing Analysis
- 7. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
- 8.1. Inactivated
- 8.2. Attenuated
- 8.3. Subunit
- 8.4. DNA
- 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Pathogen
- 9.1. Bacteria
- 9.2. Virus
- 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Species
- 10.1. Salmon
- 10.2. Tilapia
- 10.3. Trout
- 10.4. Sea Bass
- 10.5. Carp
- 10.6. Turbot
- 10.7. Bream
- 10.8. Others
- 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Route of Administration
- 11.1. Intraperitoneal
- 11.2. Intramuscular
- 11.3. Immersion
- 11.4. Oral
- 12. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by End User
- 12.1. Fish Farming Companies
- 12.2. Fish Veterinary Clinics
- 12.3. Aquatic Research Institutes
- 13. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region
- 13.1. North America
- 13.2. Latin America
- 13.3. Europe
- 13.4. East Asia
- 13.5. South Asia
- 13.6. Oceania
- 13.7. Middle East and Africa (MEA)
- 14. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 17. Rest of the World Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 18. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Hipra
- 20.2. Ceva Sante Animale
- 20.3. Vaxxinova
- 20.4. Zoetis Inc. (PharmaQ)
- 20.5. Merck Animal Health
- 20.6. Elanco Animal Health
- 20.7. AquaBounty Technologies
- 20.8. Benchmark Holdings plc
- 20.9. Tecnovax SA
- 20.10. Bluestar Adisseo Co.
- 20.11. Genentech Biotechnology
- 20.12. Hendrix Genetics BV
- 20.13. Nisseiken Co. Ltd.
- 20.14. Europharma AS
- 20.15. Fish Vet Group
- 20.16. Novartis Animal Health
- 20.17. Intervet Inc.
- 20.18. Provaxs Biotek Inc.
- 20.19. Vaki Aquaculture Systems Ltd.
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
List Of Table
Table 01: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 02: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 03: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 04: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 05: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 06: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration Age Group
Table 07: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
Table 08: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 10: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 11: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 12: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 13: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 14: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 16: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 17: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 18: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 19: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 20: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 22: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 23: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 24: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 25: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 26: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 27: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 28: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 29: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 30: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 03: Global Market Share Analysis (%), By Vaccine Type, 2024 to 2034
Figure 04: Global Market Y-o-Y Analysis (%), By Vaccine Type, 2024 to 2034
Figure 05: Global Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 06: Global Market Share Analysis (%), By Pathogen, 2024 to 2034
Figure 07: Global Market Y-o-Y Analysis (%), By Pathogen, 2024 to 2034
Figure 08: Global Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 09: Global Market Share Analysis (%), By Species, 2024 to 2034
Figure 10: Global Market Y-o-Y Analysis (%), By Species, 2024 to 2034
Figure 11: Global Market Attractiveness Analysis By Species, 2024 to 2034
Figure 12: Global Market Share Analysis (%), By Route of Administration, 2024 to 2034
Figure 13: Global Market Y-o-Y Analysis (%), By Route of Administration, 2024 to 2034
Figure 14: Global Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 15: Global Market Share Analysis (%), By End User, 2024 to 2034
Figure 16: Global Market Y-o-Y Analysis (%), By End User , 2024 to 2034
Figure 17: Global Market Attractiveness Analysis, By End User, 2024 to 2034
Figure 18: Global Market Share Analysis (%), By Route of Administration Age Group, 2024 to 2034
Figure 19: Global Market Y-o-Y Analysis (%), By Route of Administration Age Group, 2024 to 2034
Figure 20: Global Market Attractiveness Analysis By Route of Administration Age Group, 2024 to 2034
Figure 21: Global Market Share Analysis (%), By Region, 2024 to 2034
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034
Figure 24: North America Market Value Share, By Vaccine Type, 2024 (E)
Figure 25: North America Market Value Share, By Speciess 2024 (E)
Figure 26: North America Market Value Share, By Pathogen, 2024 (E)
Figure 27: North America Market Value Share, By Route of Administration, 2024 (E)
Figure 28: North America Market Value Share, By End User, 2024 (E)
Figure 29: North America Market Value Share, By Country, 2024 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 31: North America Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis By Species, 2024 to 2034
Figure 33: North America Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 34: North America Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis By End User, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 37: Europe Market Value Share, By Vaccine Type, 2024 (E)
Figure 38: Europe Market Value Share, By Speciess 2024 (E)
Figure 39: Europe Market Value Share, By Pathogen, 2024 (E)
Figure 40: Europe Market Value Share, By Route of Administration, 2024 (E)
Figure 41: Europe Market Value Share, By End User, 2024 (E)
Figure 42: Europe Market Value Share, By Country, 2024 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 44: Europe Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 45: Europe Market Attractiveness Analysis By Species, 2024 to 2034
Figure 46: Europe Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 47: Europe Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 48: Europe Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 50: Middle East and Africa Market Value Share, By Vaccine Type, 2024 (E)
Figure 51: Middle East and Africa Market Value Share, By Species, 2024 (E)
Figure 52: Middle East and Africa Market Value Share, By Pathogen, 2024 (E)
Figure 53: Middle East and Africa Market Value Share, By Route of Administration, 2024 (E)
Figure 54: Middle East and Africa Market Value Share, By End User, 2024 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 57: Middle East and Africa Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 58: Middle East and Africa Market Attractiveness Analysis By Species, 2024 to 2034
Figure 59: Middle East and Africa Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 60: Middle East and Africa Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 61: Middle East and Africa Market Attractiveness Analysis By End User, 2024 to 2034
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034
Figure 63: Rest of the World Market Value Share, By Vaccine Type, 2024 (E)
Figure 64: Rest of the World Market Value Share, By Speciess 2024 (E)
Figure 65: Rest of the World Market Value Share, By Pathogen, 2024 (E)
Figure 66: Rest of the World Market Value Share, By Route of Administration, 2024 (E)
Figure 67: Rest of the World Market Value Share, By End User, 2024 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 69: Rest of the World Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 70: Rest of the World Market Attractiveness Analysis By Species, 2024 to 2034
Figure 71: Rest of the World Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 72: Rest of the World Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 73: Rest of the World Market Attractiveness Analysis By End User, 2024 to 2034
Figure 74: United States Market Value Share, By Vaccine Type, 2024 to 2034
Figure 75: United States Market Value Share, By Species, 2024 to 2034
Figure 76: United States Market Value Share, By Pathogen, 2024 to 2034
Figure 77: United States Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 78: United States Market Value Share, By End User, 2024 to 2034
Figure 79: United States Market Value Analysis (US$ Mn), 2024 to 2034
Figure 80: Canada Market Value Share, By Vaccine Type, 2024 to 2034
Figure 81: Canada Market Value Share, By Species, 2024 to 2034
Figure 82: Canada Market Value Share, By Pathogen, 2024 to 2034
Figure 83: Canada Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 84: Canada Market Value Share, By End User, 2024 to 2034
Figure 85: Canada Market Value Analysis (US$ Mn), 2024 to 2034
Figure 86: United Kingdom Market Value Share, By Vaccine Type, 2024 to 2034
Figure 87: United Kingdom Market Value Share, By Species, 2024 to 2034
Figure 88: United Kingdom Market Value Share, By Pathogen, 2024 to 2034
Figure 89: United Kingdom Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 90: United Kingdom Market Value Share, By End User, 2024 to 2034
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 to 2034
Figure 92: Germany Market Value Share, By Vaccine Type, 2024 to 2034
Figure 93: Germany Market Value Share, By Species, 2024 to 2034
Figure 94: Germany Market Value Share, By Pathogen, 2024 to 2034
Figure 95: Germany Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 96: Germany Market Value Share, By End User, 2024 to 2034
Figure 97: Germany Market Value Analysis (US$ Mn), 2024 to 2034
Figure 98: France Market Value Share, By Vaccine Type, 2024 to 2034
Figure 99: France Market Value Share, By Species, 2024 to 2034
Figure 100: France Market Value Share, By Pathogen, 2024 to 2034
Figure 101: France. Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 102: France Market Value Share, By End User, 2024 to 2034
Figure 103: France Market Value Analysis (US$ Mn), 2024 to 2034
Figure 104: Italy Market Value Share, By Vaccine Type, 2024 to 2034
Figure 105: Italy Market Value Share, By Species, 2024 to 2034
Figure 106: Italy Market Value Share, By Pathogen, 2024 to 2034
Figure 107: Italy Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 108: Italy Market Value Share, By End User, 2024 to 2034
Figure 109: Italy Market Value Analysis (US$ Mn), 2024 to 2034
Figure 110: Spain Market Value Share, By Vaccine Type, 2024 to 2034
Figure 111: Spain Market Value Share, By Species, 2024 to 2034
Figure 112: Spain Market Value Share, By Pathogen, 2024 to 2034
Figure 113: Spain Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 114: Spain Market Value Share, By End User, 2024 to 2034
Figure 115: Spain Market Value Analysis (US$ Mn), 2024 to 2034
Figure 116: GCC Countries. Market Value Share, By Vaccine Type, 2024 to 2034
Figure 117: GCC Countries Market Value Share, By Species, 2024 to 2034
Figure 118: GCC Countries Market Value Share, By Pathogen, 2024 to 2034
Figure 119: GCC Countries Market Value Share, By Route of Administration, 2024 to 2034
Figure 120: GCC Countries Market Value Share, By End User, 2024 to 2034
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 to 2034
Figure 122: South Africa Market Value Share, By Vaccine Type, 2024 to 2034
Figure 123: South Africa Market Value Share, By Species, 2024 to 2034
Figure 124: South Africa Market Value Share, By Pathogen, 2024 to 2034
Figure 125: South Africa Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 126: South Africa Market Value Share, By End User, 2024 to 2034
Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 to 2034
Commercial Aquaculture Vaccine Market